Navigation Links
Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
Date:6/2/2008

NEW ORLEANS, June 2 /PRNewswire/ -- Dr. Charles Kerber, University of California San Diego, reported today at the American Society of Neuroradiology Conference in New Orleans the early results on the use of a new technology, Neucrylate(TM), to treat cerebral aneurysms. Neucrylate is a liquid embolic that has been developed by Valor Medical, a San Diego, CA, medical device company. "The patients have had very positive results and to date the accumulated patient implant times have reached 1400 days," Dr. Kerber stated.

The implant procedure begins by placing a microcatheter into an artery in the groin and then is passed up into the brain. This catheter is positioned in the aneurysm and Neucrylate is injected into the aneurysm. When Neucrylate comes in contact with the blood in the aneurysm it changes from a liquid to a sponge-like material. Once the catheter is in place the treatment time is approximately 1 -2 minutes.

Dr. Sean Pakbaz, University of California San Diego, has performed all the implants to date. "The more I use Neucrylate the more I'm impressed with how it works. Reducing the time it takes to treat an aneurysm is always a major goal when working in the brain. Implanting Neucrylate takes a lot less time than implanting coils. Neucrylate also fills the aneurysm compared to coils which only fill 30-40% of the aneurysm," Dr. Pakbaz stated.

Clark Adams, CEO, said, "Valor Medical is very excited with the early results from our clinical trials. Valor will be expanding the trial sites in Europe within a few months and we expect to begin trials in the U.S. later this year. The company anticipates launching Neucrylate in Europe by early 2010".

http://www.valormedical.com


'/>"/>
SOURCE Valor Medical
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related medicine technology :

1. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Globus Medical Raises $110 Million in Series E Financing Round
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCal...d favorable initial results from the first stage o...e safety and immunogenicity of the company,s 2009 ...vaccine. Novavax is conducting this study in coll...pport registration of the vaccine in Mexico and po...
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/1/2009)... , MONTREAL and DUSSELDORF, Germany, ...eading manufacturer of specialized graphics soluti...mbH is now shipping the Matrox Xenia(TM) Series d...S and Mammography solutions using Fujifilm Synaps... in computer based radiography, offering the world...
Breaking Medicine Technology:NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3FUJIFILM Europe Teams Synapse with Matrox Xenia 2FUJIFILM Europe Teams Synapse with Matrox Xenia 3Wistar Institute team finds key target of aging regulator 48508 1Wistar Institute team finds key target of aging regulator 48508 2CAP Announces Health Care Reform Agenda 48504 1CAP Announces Health Care Reform Agenda 48504 2CAP Announces Health Care Reform Agenda 48504 3FDA Panel Mulls Newer Antipsychotics for Kids 48499 1FDA Panel Mulls Newer Antipsychotics for Kids 48499 2FDA Panel Mulls Newer Antipsychotics for Kids 48499 3FDA Panel Mulls Newer Antipsychotics for Kids 48499 4
...nd Associated Microbial Genomes to Understand and ...e Fuels, Biofertlizers, and Disease Control Soluti...ne Accomplishment for Partners who Announced Compl..., Calif. and KUALA LUMPUR, Malaysia, May 20 Synth... applying genomic-driven commercial solutions to a...
...monstrate that maintenance therapy with RISPERDAL(...RLAT) significantly delayed the time to relapse co...der. Results of the study were presented this week...er is a brain disorder that causes unusual shifts .... It is often characterized by debilitating mood s...
Other Medicine Technology:First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology 2First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:12/2/2009)...pellents suspected in birth defect that affects ma...Y, Dec. 2 (HealthDay News) -- Male babies of women...months of pregnancy appear to be at increased risk...s report. , This birth defect, which affects ab...ure shortening of the urethra, the tube that carri...
(Date:12/2/2009)...OR, Mich. Even when women at high-risk of breast ...its of using the drug tamoxifen for prevention, on... Researchers at the University of Michigan Compreh...ed to inform women about the risks and benefits as...d to stop breast cancer from returning and has rec...
(Date:12/2/2009)... NCDecember 2, 2009Ninety-six percent of low-incom...nder-based distrust indicated a strong general fee...s general distrust towards men did not prevent the...tic relationship. Furthermore, the union was often...," despite their prior assertions of distrust and ...
(Date:12/2/2009)...tists may not be able to tell a good book by its c...d book by its smell. In a report in ACS, Analytic...be development of a new test that can measure the ...ocuments based on their smell. The nondestructive ...erve a range of prized paper-based objects, some o...
(Date:12/2/2009)...mpions Biotechnology, Inc. (OTC Bulletin Board: CS... a predictive preclinical platform aimed at accele...oncology drugs, has established an exclusive licen...td., Tel Aviv University,s wholly owned technology...compasses the development and commercialization of...
Breaking Medicine News(10 mins):Health News:High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds 2Health News:Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug 2
...ll gain access to innovative medical, education an...st satellite, radio channel created for medical pr...ug. 27 ReachMD XM 157 announced today a new,strat...ians-in-training., Gary Epstein, CEO of ReachMD, ...
...apeutic Radiology and Oncology has selected renown... 2008 honorary member. Dr. Evans will be recognize...er 23, at 10:00 a.m. during ASTRO,s 50th Annual Me...e original Ronald McDonald House, which opened in ...
...of preterm birth cuts risk in half, study finds , ...agnesium sulfate, given to mothers at risk of pret...eir babies by nearly half, a new study found. , "I...ir child from having cerebral palsy," said study l...
...ated with treating ,wet, form of the eye disease ,...Scientists from the United States and China have i...the onset of severe "dry" macular degeneration, on...n work with both human and mice cells, centers on ...
...CT Corporation,(Nasdaq: DRRX ) today reported tha..., has submitted an Investigational New Drug (IND) ...on (FDA) for an abuse-resistant opioid,pain drug c... Pain Therapeutics, for which King Pharmaceuticals...
...e it or not,women and men have different oral heal...e at different stages throughout their life, inclu...ylvania Dental Association (PDA) offers a reminder...they,need to maintain healthy teeth and gums., Ch...
Other Medicine News:Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3Health News:DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology 2Health News:DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology 3Health News:What You Need to Know About Women's Oral Health 2
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: